Cardium expands wound healing and tissue regeneration portfolio Cardium Therapeutics announced that it has gained exclusive access to commercial development privileges for several novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to 3 weeks, to broaden and expand the business’s wound healing and cells regeneration portfolio. Nitric oxide is usually a physiological mediator that has been shown to play an important part in enhancing wound curing. ‘We are excited about the potential for the commercial advancement of this nitric oxide therapy initiative for wound curing and cells regeneration.Lead items are directed toward a genuine amount of clinical indications like the treatment of chronic discomfort and overactive bladder; markets that approached $2 billion in worldwide income by the finish of 2013. Related StoriesSpotting the outward symptoms of advanced prostate malignancy: an interview with Brian TomlinsonIdentifying obstructive coronary artery disease in ladies: an interview with Dr. Ladapo, NYU College of MedicineInner ear harm human brain warnings from nerve cells Axonics founders are the former senior administration group of Vessix Vascular, Inc., that was obtained by Boston Scientific Corp.




COMPANY PROFILE | CUSTOMER SERVICE | PRODUCTS
LEADING PRODUCTS | CATALOGUE | TO CONTACT US

info@uniformetecnic.com